ANALYZING THE THERAPEUTIC EFFICACY OF ROSUVASTATIN IN MANAGING HYPERCHOLESTEROLEMIA AND DYSLIPIDEMIA

Аннотация

This research aimed to assess both the clinical effectiveness and safety of rosuvastatin therapy in patients diagnosed with hypercholesterolemia and dyslipidemia. The study involved 60 participants treated at the therapeutic unit of Bukhara City Clinical Hospital between 2024 and 2025. Subjects were randomly assigned to two groups: the first group (n=30) received daily doses of rosuvastatin (10–20 mg), while the second group (n=30) underwent lifestyle and dietary interventions without medication. The key parameters analyzed included changes in lipid profiles — specifically total cholesterol, LDL-C, and HDL-C —along with liverenzyme levels toensure drug safety. At baseline, lipid indicators were similar between both groups. After 12 weeks, those treated with rosuvastatin demonstrated marked improvements: total cholesterol levels dropped by 28%, LDL-C was reduced by 44%, and HDL-C rose by 27%, all with statistically significant differences (p < 0.05). The lifestyle-only group did not show meaningful changes in these metrics. The medication was well tolerated overall, with only mild adverse reactions observed in two individuals, none of which required stopping the therapy. These results reinforce the established lipid-lowering potential of rosuvastatin and affirm its safety in everyday clinical settings. The study highlights that rosuvastatin therapy yields significantly better improvements in lipid profiles than non-pharmacological measures alone. Therefore, it should be regarded as a key element in the prevention of atherosclerosis and cardiovascular complications, especially for patients at heightened risk. Further extensive, long-term trials are recommended to validate the durability of these benefits and track long- term safety outcomes. Keywords: rosuvastatin, hypercholesterolemia, dyslipidemia, atherosclerosis, lipid profile, prevention. Introduction. Atherosclerosis and its associated cardiovascular diseases (CVD) remain among the primary causes of illness and premature death worldwide, contributing significantly to disability and early mortality. The development of atherosclerosis is driven by a complex set of factors, including lipid metabolism disorders, endothelial dysfunction, chronic inflammation, and genetic predisposition. Among the modifiable risk factors, dyslipidemia plays a central role. It is typically characterized by elevated levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglycerides, along with reduced levels of high-density lipoprotein cholesterol (HDL-C). This lipid imbalance contributes to the formation and progression of atherosclerotic plaques in the arteries, leading to vascular narrowing and ischemic events suchas myocardial infarction and stroke. 98,7:ROTCAFTCAPMI .SECNEICSLACIDEM ,5202, enuJ,5emuloV gro.srehsilbupcimedaca.www Pharmacological management of dyslipidemia has become a cornerstone of cardiovascular disease prevention. Statins, or HMG-CoA reductase inhibitors, are the first-line agents due to their proven ability to reduce LDL-C, stabilize atherosclerotic plaques, and exert additional effects such as anti-inflammatory action and improved endothelial function. Among these, rosuvastatin stands out for its high potency, favorable pharmacokinetic properties, and strong lipid-lowering efficacy even at low doses. It works by inhibiting the rate-limiting step in cholesterol biosynthesis, resulting in marked reductions in LDL-C and totalcholesterol, as well as beneficial effects onHDL-C and triglyceride levels. Although the effectiveness and safety of rosuvastatin have been confirmed in large-scale clinical trials, continued evaluation in various clinical contexts and patient populations remains important. Factors such as genetic variability, comorbid conditions, and concurrent medications can influence treatment response and tolerability. Therefore, this study is dedicated to assessing the clinical and laboratory efficacy and safety of rosuvastatin in patients with dyslipidemia undergoing treatment in a city clinical hospital. The results are intended to support the optimization of lipid management strategies tailored to the specific needs of thelocal patient population. Materials andMethods This prospective, controlled study was conducted at the Therapeutic Department of Bukhara City Clinical Hospital during the period from 2024 to 2025. A total of 60 patients diagnosed with primary dyslipidemia or hypercholesterolemia were enrolled based on the diagnostic criteria established by the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) in 2016. The inclusion and exclusion criteria were rigorously applied to ensure ahomogeneous studypopulation and minimizeconfounding factors. Inclusion criteria were as follows: patients aged between 35 and 70 years; total cholesterol levels exceeding 5.2 mmol/L; LDL cholesterol levels above 3.0 mmol/L; and no prior history of statin therapy, allowing for an unbiased assessment